Document is current
Any future updates will be listed below
-
Authors
Kember, Rachel L. https://orcid.org/0000-0001-8820-2659
Vickers-Smith, Rachel
Xu, Heng
Toikumo, Sylvanus
Niarchou, Maria https://orcid.org/0000-0002-8855-7393
Zhou, Hang https://orcid.org/0000-0002-7694-6391
Hartwell, Emily E. https://orcid.org/0000-0002-5137-9714
Crist, Richard C.
Rentsch, Christopher T. https://orcid.org/0000-0002-1408-7907
,
Davis, Lea K.
Justice, Amy C. https://orcid.org/0000-0003-0139-5502
Sanchez-Roige, Sandra https://orcid.org/0000-0001-6137-5699
Kampman, Kyle M.
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (K01 AA028292)
U.S. Department of Veterans Affairs (I01 BX003341)
U.S. Department of Veterans Affairs (I01 CX001734)
U.S. Department of Veterans Affairs (I01 BX003341)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P30 DA046345)
- License Information
-
More Information
Article History
Received: 16 December 2021
Accepted: 11 August 2022
First Online: 28 September 2022
Competing interests
: H.R.K. is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes, and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi and Otsuka. J.G. and H.R.K. are holders of US patent no. 10,900,082 titled: ‘Genotype-guided dosing of opioid agonists,’ issued 26 January 2021. The other authors declare no competing interests.
